Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

References

• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Miniño BAM, Murphy SL, Jiaquan X, et al. Deaths: final data for 2008. Natl Vital Stat Rep 2011;59:1-157
   PubMedGoogle Scholar
• Miyazaki S, Ito T, Suwa M, et al. Role of transesophageal echocardiography in the prediction of thromboembolism in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J 2001;65:874-8
   PubMedGoogle Scholar
• CET Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989;46:727-43
   PubMedGoogle Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice. Circ 2006;114:e257-354
   PubMed Web of Science ®Google Scholar
• Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur H J 2006;27:949-53
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
   PubMed Web of Science ®Google Scholar
• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883-91
   Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-2
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Highlights of Prescribing Information. PRADAXA® (dabigatran etexilate mesylate) capsules for oral use. Initial U.S. Approval: 2010. Ridgefield, Connecticut; 2011
   Google Scholar
• Janssen Pharmaceuticals, Inc. Highlights of Prescribing Information. XARELTO (rivaroxaban) film-coated oral tablets. Initial U.S. Approval: 2011. Titusville, NJ; 2011
   Google Scholar
• Centers for Medicare and Medicaid Services. Medicare Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing. 2010. http://www.medicarepaymentandreimbursement.com/2010/05/medicare-payment-for-e-m-code-99201.html. Accessed January 11, 2012
   Google Scholar
• Consumer Price Index December 2010. USDL-11-0018. Bureau of Labor Statistics US Department of Labor. http://www.bls.gov/news.release/archives/cpi_01142011.pdf. Accessed January 11, 2012
   Google Scholar
• Chiong JR, Kim S, Lin J, et al. Evaluation of costs associated with Tolvaptan-mediated length of stay reduction among heart failure patients with Hyponatremia in the US, based on the EVEREST Trial. J Med Econ 2012;15:1-9
   Google Scholar
• Dasta JF, Chiong JR, Christian R, et al. Evaluation of costs associated with Tolvaptan- mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 Trials. Hospit Pract 2012:40:1-8
   Google Scholar
• Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edn. Chest 2008;133(6 Suppl):546S-92S
   PubMedGoogle Scholar
• Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049-56
   PubMed Web of Science ®Google Scholar
• Zimetbaum PJ, Thosani A, Yu H-T, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010;123:446-53
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. New Engl J Med 2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-8
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401
   PubMed Web of Science ®Google Scholar
• Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996;132:1095-100
   PubMed Web of Science ®Google Scholar
• Melamed OC, Horowitz G, Elhayany A, et al. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011;17:232-7
   PubMed Web of Science ®Google Scholar
• Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
   PubMed Web of Science ®Google Scholar
• Berg AM. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:570, author reply 570-1
   Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Throm Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY Trial. New Engl J Med 2010;363:1875-6
   PubMed Web of Science ®Google Scholar
• FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). NDA 202439: XARELTO® (rivaroxaban) Tablets
   Google Scholar
• Earnshaw SR, Scheiman J, Fendrick AM, et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011;171:218-25
   PubMedGoogle Scholar
• Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86.
   PubMed Web of Science ®Google Scholar